Losartan Potassium Tablet, Film Coated
Product Images NDC 71610-155

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71610-155). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 25 mg (71610 0155 30)

Label for Losartan Potassium USP 25 mg film-coated tablets. The label shows the product strength as 25 mg and package count of 30 tablets. It is labeled for prescription use only and indicates storage instructions and manufacturer details, including Hetero Labs Limited in India and repackaging by Aphena Pharma Solutions in Tennessee.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Losartanaddress1 (Losartanaddress1)

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over a 60-month study period between Atenolol (dotted line) and Losartan Potassium (solid line). The chart includes an adjusted risk reduction of 13% with a p-value of 0.021, indicating statistical analysis of treatment efficacy.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal/non-fatal stroke over 66 study months for Atenolol and Losartan potassium. It shows a lower incidence of stroke in patients treated with Losartan potassium compared to Atenolol, with an adjusted risk reduction of 25% and a p-value of 0.001.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A forest plot figure titled 'Primary Endpoint Events within Demographic Subgroups' showing hazard ratios (with 95% confidence intervals) comparing Losartan Potassium and Atenolol for primary composite and stroke (fatal/non-fatal) events. The plot includes multiple demographic subgroups such as age, gender, race, ISH, diabetes, and history of cardiovascular disease, with event rates and hazard ratios visually represented by squares and diamonds along a horizontal axis indicating favorability towards Losartan or Atenolol.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph comparing the percentage of patients with an event over 48 months between Losartan Potassium and placebo groups. The vertical axis shows the percentage of patients with events, and the horizontal axis shows time in months. The graph indicates risk reduction of 16.1% with a p-value of 0.022 for Losartan Potassium versus placebo.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure of Losartan Potassium shown as a line drawing featuring ring structures and various substituents, including potassium ion (K+). This image depicts the molecular framework of the active ingredient Losartan Potassium.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.